http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104096048-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a7355b3d88d9992c7d7f1e63abc869
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
filingDate 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_102c9901f9b6d0e1585b5bea277a0d44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58d2386396b9a9ac552d72f4792b6b2f
publicationDate 2014-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104096048-A
titleOfInvention Quick-acting wound hemostatic anti-inflammatory analgesic powder
abstract The invention discloses a quick-acting wound hemostatic anti-inflammatory analgesic powder, which is prepared by: taking 18%-20% of aizoon stonecrop herb, 40%-42% of jujube tree bark, Chinese angelica 20%-22% of, and 18%-20% of paris polyphylla as raw materials, and subjecting the materials to drying, crushing, extraction and mixing to obtain the wound hemostatic anti-inflammatory analgesic powder, which has the advantages of good hemostatic, anti-inflammatory and analgesic effects, rapid wound healing promotion, no wound suppuration and infection, and especially strong hemostatic capacity. The formed scab is tightly and powerfully combined with surrounding skin, is difficult to fall off, and can prevent water soaking, thus reducing the chance of infection. And the wound surface granulation is fresh, and the epithelium grows well. The hemostatic anti-inflammatory analgesic powder provided by the invention is suitable for hemostasis, inflammation diminishing and analgesia of various wounds, and has the advantages of obvious curative effect, quick healing, no adverse reaction, and no side effect.
priorityDate 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962

Total number of triples: 18.